Purpose
RefinedScience combines high-fidelity data with cutting-edge science & technology and world-class expertise to inform smarter drug discovery & development. Our transformative insights identify & validate novel drug targets, design smarter clinical trials, and forge paths for stalled clinical-stage drug candidates. Our approach can significantly increase the probability of success while shaving off millions of dollars and years in the process.
PROBLEM: Drug development is SLOW, COSTLY, and RISKY:
- $161B spent on R&D by largest pharma companies in 2023.
- +8.5% increase in R&D costs per year over last decade
- $200B annual revenue at risk through 2030 from looming patent cliffs
- ~96% of oncology programs fail in the clinic
With evolving science & technology, we better understand how disease, patient, & cell diversity impacts diagnosis, response, resistance, and metastasis; however, clinical trials are often not informed with these insights. Additionally, a single person may generate terabytes of healthcare data, but defining, structuring, & analyzing this data to produce actionable insights continues to be a challenge.
A MORE REFINED, SMARTER APPROACH IS NEEDED…
Platform
RefinedScience has built a comprehensive platform dedicated to the generation of advances and new insights.
.png)
HIGHLY CURATED PATIENT DATA
Our high-fidelity, curated, deep, fit-for-purpose data provide a comprehensive view of disease heterogeneity and precision patient targeting, and serve as the engine for our innovation and differentiation.
- CLINICAL DATA: We have curated clinical data from diverse, real-world sources, including a unique and dynamic live-stream feed from a large, regional hospital system. We also ingest, structure, and analyze data from pharma & industry partners, federated data, clinical trials, etc., enabling us to accumulate hundreds of clinical data points per patient.
- BIOLOGIC SINGLE CELL DATA: We have constructed the most expansive single-cell omics dataset in Acute Myeloid Leukemia (AML), including genomics, transcriptomics, proteomics, etc. with millions of data points per patient derived from a continuously replenished biobank of tissue samples. Our partnership with hospital systems & others enables us to replicate these one-of-a-kind datasets across diseases, e.g. hematology, oncology, immunology, neuroscience, etc.
CUTTING EDGE TECHNOLOGY & DATA PROCESSING
We have created a team of expert data scientists to apply cutting-edge science and technology to the analysis of deep data, including the use of artificial intelligence (AI), machine learning (ML), and predictive models of toxicity and outcomes. Our approach includes:
- Identification, abstraction, curation, and harmonization of data
- Interrogation of data to discover patterns, trends, and correlations
- Generation of transformative insights, advances, and new tools.
WORLD-LEADING EXPERTS
Our transformative insights could not be discovered were it not for our world-class multi-disciplinary team of academic & industry experts. We have built a team of the best and brightest minds in bioinformatics, AI, molecular/cellular biology, clinical care, and innovation, including partnerships with world-renowned KOLs.
PROVEN, SCALABLE MODEL
Our transformative approach to precision drug development is proven and scalable. Take, for instance, our work in Acute Myeloid Leukemia (AML):
- AML patients have poor survival rates and can develop resistance to standard of care targeted therapies. RefinedScience leveraged its proprietary, world-class AML dataset to uncover important targets, such as CD70, for patients who develop resistance.
- RefinedScience took these insights to Argenx with a CD70 drug candidate, cusatuzumab, that suggested promising results in a Phase 1b study. Argenx and RefinedScience agreed to spin off a new joint venture (JV) called OncoVerity.
- Applying RefinedSciences transformative insights, OncoVerity designed a smart Phase 2 trial enriching for patients with unmet medical need with the potential for responses, increasing the probability of success.
Partner
DRIVING VALUE ACROSS ALL STAGES OF DRUG DISCOVERY & DEVELOPMENT
RefinedScience’s cutting-edge analytics, correlative science, and transformative, data-driven insights can help identify and validate novel drug targets, inform smarter clinical trial design, salvage halted/stalled clinical-stage ./assets, bring value to clinical decision-making for payers, providers, etc.
WHAT MAKES US UNIQUE
While a growing number of companies are leveraging health data and AI to inform drug development…
ONLY REFINEDSCIENCE HAS THE S.M.A.R.T. ADVANTAGE:
The largest, deepest, and highest fidelity datasets in hematological cancers, including genomics, transcriptomics, proteomics, etc., with the ability to build similar data sets in expanding indications
Focus on areas of high unmet medical need to inform shorter trials with quicker readouts and higher probability of success.
Dynamic data feed from health system, biological samples across disease indications, and ability to digest a wide array of real-world and clinical trial data.
Next generation single cell sequencing, in vitro/in vivo testing, animal models, and wet lab studies done by our team of expert scientists using a bank of patient tissue and blood samples.
World-class multi-disciplinary team of academic & industry experts in bioinformatics, AI, molecular/cellular biology, clinical care, and innovation, including partnerships with leading KOLs.
PARTNER WITH US
At RefinedScience, we aim to maximize patient impact with unique insights that optimize clinical trial probability of success and time to actionable results by seamlessly integrating top-tier clinical and biological data with expert knowledge. We are your trusted partner in achieving better results, faster – working together to unlock your strategic advantage. Let’s start the conversation. Contact us here: Partnerships@RefinedScience.com
People
At RefinedScience, we have a passion for advancing care by bringing together the best science, data, and minds - disease by disease, patient by patient, cell by cell.
RefinedScience has built a world-class, multi-disciplinary team of academic & industry experts in bioinformatics, AI, molecular/cellular biology, clinical care, and innovation, including partnerships with renowned KOLs.
We are guided by our core values:
- Act with purpose
- Be curious
- Take ownership
- Invest in relationships
- Embrace agility
Meet our team
Erik Johnson is a results-driven commercial leader with 20+ years in pharmaceuticals, with roles in sales, marketing, operations and strategy. He has delivered $3B+ in incremental U.S. and global sales through successful oncology product launches (SPRYCEL, YERVOY, YERVOY+OPDIVO) and scaled all aspects of a startup to pivot from R&D to a successful commercial launch.
Clay Smith, MD is a Professor in the Division of Hematology at the University of Colorado (CU), the Medical Director of CU Innovations and served as the Director of the Blood Disorders and Cell Therapies Center at UCHealth and CU for the past decade. He has authored >150 manuscripts, received dozens of grants, and holds numerous patents and is focused on developing novel therapies for blood cancers using omics technologies integrated with clinical data and cutting-edge computational tools.
Grant Weller, PhD has led highly skilled, multidisciplinary technical teams in healthcare for over 10 years and scaled multiple new data-driven technologies in the health benefits and medical device industries. He has held previous roles with Savvysherpa, UnitedHealth Group, and BioIntellliSense. He holds a PhD in Statistics from Colorado State University.
Sanjay Zaveri is an accomplished leader and business executive with 25+ years of pharmaceutical experience across commercial strategy, new product planning, pricing, business development, licensing and M&A. He has a broad & active global network across pharmaceutical & biotech executives, key stakeholders, and investors and has experience in Oncology, Immunology, Neurology, Cardiovascular and Rare Disease. Sanjay has managed over $1B in strategic transactions during his career.
Kimberly Muller, Esq. is the Executive Director of CU Innovations, leading innovation for the University of Colorado Anschutz Medical Campus. She manages over $235 million throughout several venture investment funds and brings vast experience in investing, company creation, innovation management, forming key strategic industry partnerships, and licensing.
© 2024 RefinedScience. All Rights Reserved. | Cookie Policy